Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV002047869 | SCV002289061 | likely benign | Noonan syndrome 9 | 2023-04-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002346278 | SCV002621863 | uncertain significance | Cardiovascular phenotype | 2021-06-12 | criteria provided, single submitter | clinical testing | The p.N1233T variant (also known as c.3698A>C), located in coding exon 23 of the SOS2 gene, results from an A to C substitution at nucleotide position 3698. The asparagine at codon 1233 is replaced by threonine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV002047869 | SCV002762982 | uncertain significance | Noonan syndrome 9 | criteria provided, single submitter | clinical testing | ||
Revvity Omics, |
RCV002047869 | SCV003822089 | uncertain significance | Noonan syndrome 9 | 2021-03-18 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003992601 | SCV004811435 | likely benign | not provided | 2024-03-01 | criteria provided, single submitter | clinical testing | SOS2: BP4 |